Evidence map›Paper›PMID 35441932›Full record

Trial reportScience China. Life sciences2022

A third high dose of inactivated COVID-19 vaccine induces higher neutralizing antibodies in humans against the Delta and Omicron variants: a Randomized, Double-Blinded Clinical Trial.

Yu Cao, Xiaoli Wang, Siqi Li, Yuan Dong, Yonghong Liu, Jing Li, Yanqing Zhao, Yingmei Feng

Open access · bronzeAbstract readLetterRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Science China. Life sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 12 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Review
  6. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Yu Cao *Department of Science and Technology, Beijing Youan Hospital, Capital Medical University, Beijing, 100069, China.
Xiaoli Wang *Beijing Center for Disease Prevention and Control, Beijing, 100013, China.
Siqi Li *Beijing Center for Disease Prevention and Control, Beijing, 100013, China.
Yuan DongDepartment of Science and Technology, Beijing Youan Hospital, Capital Medical University, Beijing, 100069, China.
Yonghong LiuBeijing Center for Disease Prevention and Control, Beijing, 100013, China.
Jing LiSinovac Biotech Co, Ltd, Beijing, Beijing, 100085, China.
Yanqing ZhaoSinovac Biotech Co, Ltd, Beijing, Beijing, 100085, China.
Yingmei FengDepartment of Science and Technology, Beijing Youan Hospital, Capital Medical University, Beijing, 100069, China. yingmeif13@ccmu.edu.cn.
Beijing Center for Disease Prevention and Control · CNBeijing YouAn Hospital · CNSinovac Biotech · CNCapital Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

COVID-19COVID-19 VaccinesAntibodies, NeutralizingAntibodies, ViralHumansSARS-CoV-2Antibodies, NeutralizingAntibodies, ViralCOVID-19 Vaccines

Identifiers

PMID35441932
PMCPMC9020148
OpenAlexW4224223797

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.